Emergent BioSolutions and Profectus BioSciences announced a new collaboration with CEPI, the Coalition for Epidemic Preparedness Innovations, under which they will receive up to $36M to advance the development and manufacture of a vaccine against the Lassa virus-an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year. Profectus will receive development funding from CEPI for advancing its Lassa virus vaccine. CEPI will provide $4.3M to support the first phase of the project, with options to invest up to a total of $36M over five years, including procurement of the vaccine for stockpiling purposes. Emergent will provide technical and manufacturing support for the CEPI-funded program. Through a separate agreement with Profectus, Emergent has an exclusive option to license and to assume control of development activities for the Lassa-virus vaccine from Profectus.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.